CN114917403A

CN114917403A - Mussel-like mucin gel as well as preparation method and application thereof

Info

Publication number: CN114917403A
Application number: CN202210622807.3A
Authority: CN
Inventors: 王毅; 黄文涛; 乔保坤; 宗奕珊
Original assignee: Hunan Keyan Chuangmei Medical Technology Co ltd
Current assignee: Hunan Keyan Chuangmei Medical Technology Co ltd
Priority date: 2022-06-01
Filing date: 2022-06-01
Publication date: 2022-08-19

Abstract

The invention relates to a mussel-like mucin gel, a preparation method and application thereof, and relates to the technical field of biomedical materials. The mussel-like mucin gel comprises the following components in parts by weight: 1-50 parts of mussel-like mucin, 5-80 parts of gelling agent, 5-30 parts of cosolvent, 1-15 parts of protein protective agent, 1-15 parts of pH regulator and 75-3300 parts of auxiliary solvent. The preparation method of the mussel-like mucin gel comprises the steps of freeze-drying the gel into powder or separating sponge and auxiliary solvent; mussel-like mucin exists in the freeze-dried powder or sponge, can be sterilized by low-dose irradiation, can be stored at normal temperature, and can be effectively prevented from being degraded or oxidized, crosslinked and separated out during the storage period by freeze-dried powder or sponge; the invention also prepares different mussel-like mucin gels by matching different freeze-dried powders or sponges with auxiliary solvents, and can be applied to preparing products for wound repair, soft tissue filling, bone repair and the like.

Description

Mussel-like mucin gel as well as preparation method and application thereof

Technical Field

The invention relates to the technical field of biomedical materials, in particular to mussel-like mucin gel and a preparation method and application thereof.

Background

The traditional dressing has obvious defects, such as incapability of keeping the wound surface moist and delaying wound surface healing, easy growth of granulation tissues of the wound surface into meshes of the dressing, easy adhesion with the wound surface when the dressing is replaced, damage to the regenerated granulation tissues and pain; the dressing has poor barrier effect after permeation, is easy to cause exogenous infection and has poor hemostatic effect. In order to solve the problems, the novel medical dressing is developed according to the moist healing concept and can keep the wound surface moist. In recent years, the rapid development of materials and industry has led to epoch-making changes in wound dressings, and various novel dressings have come into existence and are actively used in clinic.

As people age, the moisture content, collagen and the like in the skin gradually decrease, so that the skin of people is lack of moisture, dull, dry and lusterless, and even can form large and small wrinkles. With the improvement of living standard and the improvement of medical science and technology, more and more people can select an operation mode to improve the facial contour, and the facial soft tissue filling is one of the existing minimally invasive treatment methods for treating facial volume tissue loss, contour change and static wrinkles. The ideal soft tissue filling material has good biocompatibility, effectiveness and safety.

Sodium hyaluronate dressings, collagen dressings and implants are widely used in the market at present, and can well promote wound healing or be used for filling and removing wrinkles on the face. But the huge potential market is urgently needed to enrich the whole medical and aesthetic market with more abundant and diverse new raw materials, which have been manufactured by J H, Waite; m L, Tanzer and his colleagues initiate creative research on mussel mucin called as ocean soft gold, which finds that the mussel mucin is rich in dopa group and has a large amount of positive charges due to the molecular characteristics of the mussel mucin, can effectively promote wound healing, has strong biocompatibility and low cytotoxicity, and self-crosslinking mussel mucin microspheres formed after oxidation can well fill and remove wrinkles of fine wrinkles on the face, so the mussel mucin microspheres have a very high application prospect, but also have active dopa group in the molecule, are easy to oxidize and crosslink so as to lose related functions, and can cause protein to be precipitated from solution due to oxidation and crosslinking; therefore, the transportation and storage conditions of the mussel mucin product are very strict; and the traditional sterilization modes such as irradiation, damp heat and the like can cause protein degradation or oxidative crosslinking precipitation. The preservation of mussel mucin is a major factor that limits its use.

Therefore, it is urgently needed to provide a solution which can be stored at normal temperature and is easy to transport, and can effectively avoid degradation or oxidative crosslinking precipitation of protein molecules in the storage period, and simultaneously widen the application range and simplify the process operation for the above problems of the mussel mucin.

Disclosure of Invention

In order to solve the technical problems, the invention provides a preparation method of mussel-like mucin gel, which is characterized in that the gel is lyophilized into powder or sponge and auxiliary solvent are separated; mussel-like mucin exists in the freeze-dried powder, can be sterilized by low-dose irradiation, the product can be stored at normal temperature, and the freeze-dried powder or sponge can effectively avoid the degradation or oxidation crosslinking precipitation of protein molecules in the storage period.

The invention also provides a mussel-like mucin gel, the main material of which is mussel-like mucin, which is a gene recombinant fp-151 type, and is a recombinant protein consisting of 6 MAP1 type (fp-1) decapeptide repetitive sequences at C end and N end of MAP5 type (fp-5), the recombinant hybrid protein has high expression level, simple purification and high biocompatibility, and the protein is mainly prepared by adopting escherichia coli engineering bacteria subjected to gene recombination through biological fermentation and purification; in addition, the mussel mucin has the same amino acid sequence as the naturally extracted mussel mucin, has good biocompatibility, effectiveness and safety, and can be used for wound repair, soft tissue injection filling wrinkle removal or moulding, bone defect injection filling repair and the like.

The invention also prepares different mussel-like mucin gels by matching different freeze-dried powders with auxiliary solvents, and can be applied to the aspects of wound repair, soft tissue filling, bone repair and the like.

In order to solve the technical problem, the following steps are specifically performed:

a mussel-like mucin gel comprises the following components in parts by weight:

1-50 parts of mussel-like mucin, 5-80 parts of gelling agent, 5-30 parts of cosolvent, 1-15 parts of protein protective agent, 1-15 parts of pH regulator and 75-3300 parts of auxiliary solvent;

the protein protective agent is at least one selected from trehalose, alginate oligosaccharides, sorbitol, mannitol, superoxide dismutase, vitamin C, vitamin E and tea polyphenols.

Preferably, the mussel-like mucin is a gene recombinant fp-151 type, and is a recombinant protein consisting of 6 MAP1 type (fp-1) decapeptide repeats of the C end and the N end of MAP5 type (fp-5).

The mussel-like mucin can be a recombinant mussel-like mucin as disclosed in patent publication No. CN 114349836A.

Preferably, the gelling agent is at least one selected from hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxypropyl methyl cellulose, xanthan gum, sodium alginate, sodium polyacrylate, carbomer, polyvinyl alcohol, polyvinylpyrrolidone or other nonionic thickening agent.

Preferably, the protein protective agent is trehalose, or a mixture containing trehalose and at least one of alginate oligosaccharide, sorbitol, mannitol, superoxide dismutase, vitamin C, vitamin E and tea polyphenol.

Namely, the protein protective agent at least comprises trehalose, and further, the ratio of the trehalose to other protein protective agents is 0.2-1.5: 1.

the method of combining trehalose with other protein protective agents is adopted, on one hand, trehalose is used as non-reducing disaccharide, has the functions of stabilizing cell membrane and protein structure, enhancing the resistance of cells to severe environments such as high temperature, dryness, high cold, high osmotic pressure and the like, and can effectively protect the damage of the freeze-drying process to protein; the brown algae oligosaccharide, sorbitol, mannitol, superoxide dismutase, vitamin C, vitamin E and tea polyphenol can effectively protect dopa groups in mussel-like mucin from being oxidized, so that the stability of the mussel-like mucin in the system is enhanced. Through the synergistic use of trehalose and other protein protective agents, degradation and/or reunion of class mussel mucin have effectively been avoided in irradiation and the product storage process and have been separated out, simultaneously, combine freeze-drying protection, and class mussel mucin's structure, biological function and product stability can effectively be kept in the gel system, can stably store at normal atmospheric temperature environment for a long time.

Preferably, the cosolvent is at least one selected from polyethylene glycol, glycerol, propylene glycol, butanediol, pentanediol and glyceryl polyether-26; the pH regulator is at least one selected from citric acid, boric acid, acetic acid, phosphoric acid and hydrochloric acid; the auxiliary solvent is at least one selected from normal saline, phosphate buffer and water for injection.

The invention also discloses a preparation method of the mussel-like mucin gel, which sequentially comprises the following steps:

(1) preparing freeze-dried powder or freeze-dried sponge: adding mussel-like mucin, a protein protective agent and a pH regulator into the first auxiliary solvent for dissolving, and filtering and sterilizing to obtain a solution A;

mixing the gel forming agent and the cosolvent, adding the mixture into the second auxiliary solvent, stirring, and performing damp-heat sterilization to obtain a solution B;

mixing the solution A and the solution B, and then freeze-drying and sterilizing to obtain freeze-dried powder or freeze-dried sponge;

the auxiliary solvent is divided into three parts, namely a first part of auxiliary solvent, a second part of auxiliary solvent and a third part of auxiliary solvent;

(2) preparing a gel: and mixing the sterilized third auxiliary solvent with the freeze-dried powder or the sponge to obtain the mussel-like mucin gel.

Preferably, in step (1), the filter sterilization conditions are as follows: pH 5.0-7.0, filtering with 0.1-0.45 μm membrane for sterilization; the moist heat sterilization conditions are as follows: the sterilization temperature is 105-; the sterilization is irradiation sterilization, and the irradiation dose is 5.2-14.2 KGy.

Preferably, the pH of the solution A in the step (1) is 5.0-7.0. The inventor discovers through multiple experimental researches that by adjusting the pH of the solution A within a reasonable range, the mussel mucin can be ensured to be stably present in the solution A without precipitation, and the pH value accords with the physiological pH value of skin and/or tissues.

Preferably, in step (1), the lyophilization process conditions are as follows: pre-freezing at-10 deg.C to-65 deg.C for 10-60min, sublimation drying at-10 deg.C to-60 deg.C for 12-48 hr, sublimation drying at vacuum degree of 0.1-20Pa, desorption drying at 15-45 deg.C for 3-10 hr, and desorption drying at vacuum degree of 0.1-10 Pa.

By adopting the freeze-drying process, the freeze-dried product has no shrinkage or collapse phenomenon, the appearance is smooth, the redissolution time can be controlled within 1-3 min (the redissolution time of the product obtained by the conventional freeze-drying parameters is more than 5min), the use preparation time of the product is shortened, and the clinical use is facilitated.

Preferably, in the step (2), the mass ratio of the sterilized third auxiliary solvent to the freeze-dried powder or the sponge is 254: 1-10: 1.

the invention also discloses application of the mussel-like mucin gel in preparation of products for wound repair, soft tissue filling and bone repair

Has the beneficial effects that:

(1) the preparation method of the mussel-like mucin gel comprises the steps of preparing freeze-dried powder or freeze-dried sponge, separating the freeze-dried powder or freeze-dried sponge from an auxiliary solvent, and mixing the freeze-dried powder or freeze-dried sponge containing functional components such as mussel-like mucin, a protein protective agent and the like with the auxiliary solvent to form the gel before use, wherein the mussel-like mucin exists in the freeze-dried powder or sponge, so that the problem that dopa groups contained in the mussel-like mucin are easily oxidized is solved, and degradation or oxidative crosslinking precipitation of mussel-like mucin molecules in the storage period can be effectively avoided; the low-dose irradiation sterilization is adopted, and the product can be stored at normal temperature, so that the storage condition of the product is changed from special refrigeration or freezing storage into conventional normal-temperature storage, the storage and transportation cost is saved, and the use is more convenient; meanwhile, the preparation method effectively controls the number of initial pollution bacteria, so that the product can be sterilized by low-dose irradiation, the damage of high-dose irradiation to protein molecules is effectively avoided, and the stability of the protein is further ensured.

(2) The main material of the mussel-like mucin gel is mussel-like mucin. The mussel-like mucin is prepared by biological fermentation, a target strain is constructed by genetic engineering, and the mussel-like mucin is prepared by a biological fermentation technology; the mussel mucin has the same amino acid sequence as naturally extracted mussel mucin, has better biocompatibility, avoids the biological sensitization of naturally extracted proteins, contains a large amount of lysine in protein molecules to enable the protein molecules to have high positive charges, can attract crawling and growth of negatively charged cells, and has antibacterial property by the positive charges. In addition, the mussel-like mucin contains a large amount of 3, 4-dihydroxyphenylalanine (DOPA ) in the molecule, and in clinical use, the mussel-like mucin in the freeze-dried sponge is mixed with an auxiliary solvent to form a water-containing gel system, under the condition that phenolic hydroxyl groups in DOPA are oxidized into quinone, the oxidized DOPA and unoxidized DOPA are crosslinked to form a high-molecular network polymer, and the polymer forms a transparent film which allows water vapor and air to pass through and can prevent the pollution of foreign matters, bacteria and the like of foreign dust; meanwhile, the mussel-like mucin has high adhesion property, can be strongly adhered to the wound surface, and has the effects of inhibiting bacteria and promoting wound healing. In addition, the mussel-like mucin can also be used for wound repair, soft tissue injection filling wrinkle removal or plasticity, bone defect injection filling repair and the like.

(3) The invention prepares different gel materials by adjusting the proportion of the freeze-dried powder or the freeze-dried sponge and the auxiliary solvent, is suitable for different clinical purposes, can be applied to the preparation of products for wound repair, soft tissue filling, bone repair and the like, and can be used for repairing wounds after medical and art, filling and removing wrinkles of facial wrinkles as an implant, injecting, filling and repairing bone defects and the like.

Drawings

In order to more clearly illustrate the technical solution of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.

Fig. 1 is a diagram of the wound repair effectiveness of the mussel-like mucin gel-animal experiment smearing product.

Fig. 2 is a diagram of wound repair effectiveness of mussel-like mucin gel-mouse repair in animal experiments.

Fig. 3 is a view of HE section of a mussel-like mucin gel for wound healing effectiveness in animal experiments.

FIG. 4 is a comparative graph showing the appearance of the mixed solution before lyophilization in example 1, which was irradiated with different doses and stored at room temperature for 1 day, 1 month, 3 months and 6 months.

FIG. 5 is an SDS-PAGE pattern of mussel-like mucins under different treatment conditions.

FIG. 6-1 is a SDS-PAGE gel electrophoresis of lyophilized powder stored for 0 month of example 3.

FIG. 6-2 is the SDS-PAGE gel of lyophilized powder stored for 6 months in example 3.

FIG. 7 is a SDS-PAGE gel of the products after sterilization with different protein protectants.

Detailed Description

In order to more fully understand the technical contents of the present invention, the technical solutions of the present invention will be further described and illustrated with reference to the following specific embodiments.

All percentages, fractions and ratios are calculated on the total mass of the composition of the invention, unless otherwise indicated. All qualities relating to the listed ingredients are given to the content of active substance, unless otherwise specified, and therefore they do not include solvents or by-products that may be contained in commercially available materials. The term "mass percent content" herein may be represented by the symbol "%".

All molecular weights herein are weight average molecular weights expressed in daltons, unless otherwise indicated.

All formulations and tests herein occur at 25 ℃ environment, unless otherwise indicated.

The use of "including," "comprising," "containing," "having," or other variations thereof herein, is meant to encompass non-exclusive inclusions, as well as non-exclusive distinctions between such terms. The term "comprising" means that other steps and ingredients can be added that do not affect the end result. The term "comprising" also includes the terms "consisting of …" and "consisting essentially of …". The compositions and methods/processes of the present invention comprise, consist of, and consist essentially of the essential elements and limitations of the invention described herein, as well as any of the additional or optional ingredients, components, steps, or limitations described herein. The terms "potency", "performance", "effect" and "efficacy" are not distinguished from one another herein.

A mussel-like mucin gel comprises the following components in parts by weight:

1-50 parts of mussel-like mucin, 5-80 parts of gelling agent, 5-30 parts of cosolvent, 1-15 parts of protein protective agent, 1-15 parts of pH regulator and 75-3300 parts of auxiliary solvent.

The mussel-like mucin is of fp-151 type of gene recombination, which is a recombinant protein consisting of 6 MAP1 type (fp-1) decapeptide repetitive sequences of C end and N end of MAP5 type (fp-5), the expression quantity of the recombinant hybrid protein is high, the purification is simple, the biocompatibility is high, and the protein is mainly prepared by adopting escherichia coli engineering bacteria after gene recombination through biological fermentation culture, purification and freeze-drying.

Specifically, the mussel-like mucin is of fp-151 type of gene recombination, wherein the DOPA mass percentage content is 5.0-10.0%; if the DOPA content is too low, a uniform and compact three-dimensional net-shaped membrane is difficult to form through rapid crosslinking, the blocking effect on foreign matter pollution is very weak, and the DOPA content is influenced by a gene recombination technology, contains more DOPA, has higher technical difficulty and higher cost.

The gel forming agent is at least one selected from hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxypropyl methyl cellulose, xanthan gum, sodium alginate, sodium polyacrylate, carbomer, polyvinyl alcohol, polyvinylpyrrolidone or other nonionic thickening agents.

The cosolvent is at least one selected from polyethylene glycol, glycerol, propylene glycol, butanediol, pentanediol and glycerol polyether-26.

The protein protective agent is at least one selected from trehalose, alginate oligosaccharide, sorbitol, mannitol, superoxide dismutase, vitamin C, vitamin E and tea polyphenol. Preferably, the protein protectant comprises at least trehalose.

The pH regulator is at least one selected from citric acid, boric acid, acetic acid, phosphoric acid and hydrochloric acid.

The auxiliary solvent is at least one selected from normal saline, phosphate buffer and water for injection; the phosphate buffer may be selected to be a phosphate buffer at pH 7.0.

The preparation method of the mussel-like mucin gel comprises the following steps:

(1) preparing freeze-dried powder or freeze-dried sponge: adding mussel-like mucin, a protein protective agent and a pH regulator into the first auxiliary solvent for dissolving, and then filtering and sterilizing to obtain a solution A;

the auxiliary solution is divided into three parts, namely a first part of auxiliary solvent, a second part of auxiliary solvent and a third part of auxiliary solvent;

(2) preparing a gel: and mixing the sterilized third auxiliary solvent with the freeze-dried powder or the sponge to obtain the mussel-like mucin gel. Specifically, the preparation method of the mussel-like mucin gel comprises the following steps:

weighing the raw material components in proportion.

Adding mussel-like mucin, a protein protective agent and a pH regulator into an auxiliary solvent for dissolving, wherein the mass ratio of the mussel-like mucin to the auxiliary solvent is 1: 1650-1: 2, dissolving; adjusting pH to 5.0-7.0, and vacuum filtering with 0.1-0.45 μm membrane under 0.03-0.07Mpa for sterilization.

Dispersing the gel forming agent in cosolvent until no large agglomerated particles exist, adding into auxiliary solvent, heating in water bath to 50-95 deg.C, mechanically stirring at 50-500rmp for 15-120 min; then carrying out damp-heat sterilization at the temperature of 105-.

Mixing the filtered and sterilized protein solution and the wet-heat sterilized gel-forming agent, stirring for 10-25min, filling into a cavity of a prefilled syringe, and lyophilizing to obtain lyophilized powder or sponge. The freeze-drying process conditions are as follows: pre-freezing at-10 deg.C to-65 deg.C for 10-60min, sublimation drying at-10 deg.C to-60 deg.C for 12-48h, sublimation drying vacuum degree of 0.1-20Pa, desorption drying at 15-45 deg.C for 3-10h, and desorption drying vacuum degree of 0.1-10 Pa.

And (3) carrying out 5.2-14.2KGy low-dose irradiation sterilization on the freeze-dried powder or the sponge in the pre-filled syringe.

And packaging the auxiliary solvent in a penicillin bottle or an ampoule bottle, and performing damp-heat sterilization at the temperature of 105 ℃ and 130 ℃ for 5-60min to obtain the sterile auxiliary solvent.

When the mussel-like mucin gel is used, auxiliary solution in a penicillin bottle is pumped out by a prepared sterile syringe, two-component suspension is carried out by using a sterile two-way joint and freeze-dried powder or sponge pre-filled in the syringe, and the two syringes are pushed for 10-40 times to be mixed into transparent gel or milky gel, so that the mussel-like mucin gel is obtained.

The mass ratio of the sterile auxiliary solvent to the freeze-dried powder or the sponge is 254: 1-10: specifically, 1 part of freeze-dried powder or freeze-dried sponge is used as a reference, the freeze-dried powder or sponge and 150 parts of 254 parts of auxiliary solvent are mixed and can be injected into a wound surface for wound surface repair, the freeze-dried powder or sponge and 10-100 parts of auxiliary solvent are mixed and used for soft tissue filling injection wrinkle removal or shaping, and the freeze-dried powder or sponge and 100 parts of 180 parts of auxiliary solvent are mixed and used for bone defect injection filling repair.

Example 1

Accurately weighing: 10 parts of mussel-like mucin, 3200 parts of auxiliary solvent (normal saline), 18 parts of gelling agent (10 parts of methyl cellulose and 8 parts of hydroxyethyl cellulose), 6 parts of cosolvent (glycerol), 5 parts of protein protective agent (sorbitol) and 2 parts of pH regulator (citric acid).

Adding weighed citric acid, sorbitol, and mussel-like mucin into the first part of physiological saline, stirring to dissolve, controlling pH at 5.0-7.0, and performing vacuum filtration sterilization with 0.45 μm membrane under 0.03 MPa.

Adding hydroxyethyl cellulose and methyl cellulose into glycerol, dispersing until no large agglomerated particles exist, adding into a second part of normal saline, heating in water bath to 80 ℃, mechanically stirring at 400rmp for 20min to completely dissolve, and performing wet heat sterilization at 121 ℃ for 20min for later use.

Mixing and stirring the filtered and sterilized protein solution and the heat-moisture sterilized macromolecule gel-forming agent for 15min, filling the mixture into a cavity of a prefilled syringe, and freeze-drying according to the following freeze-drying parameters: prefreezing at-40 deg.C for 30min, sublimation drying at-40 deg.C for 18 hr under vacuum control of 8Pa, desorption drying at 25 deg.C under vacuum control of 1Pa for 5 hr. Freeze-drying to obtain the freeze-dried sponge. And (3) putting the freeze-dried pre-filled product into a plastic sealing bag for heat sealing, and then performing electron beam irradiation sterilization, wherein the sterilization dose is 12.5 KGy.

And packaging a third part of normal saline (1600 parts) in a penicillin bottle, performing moist heat sterilization at the temperature of 121 ℃ for 20min, and providing the sterilized saline in an aseptic mode.

When in use, the auxiliary solution in the penicillin bottle is pumped out by a prepared sterile injector, and the sterile bi-pass joint and the freeze-dried powder or the sponge bi-component pre-filled in the injector are suspended, the two injectors are pushed for 25 times to be mixed into transparent gel or milky gel, the freeze-dried powder is redissolved for 2min, and the gel is pushed into the damaged skin area and lightly smeared by hands to be uniform.

The contemplated use of this example is wound repair.

Example 2

Accurately weighing: 20 parts of mussel-like mucin, 1000 parts of auxiliary solvent (phosphate buffer solution with pH of 7.0), 8 parts of gel forming agent (hydroxyethyl cellulose), 2 parts of cosolvent (glycerol), 5 parts of protein protective agent (trehalose) and 1 part of pH regulator (acetic acid).

Adding weighed acetic acid, mannitol, mussel-like mucin into the first part of phosphate buffer solution, stirring for dissolving, controlling pH at 5.0-7.0, performing negative pressure filtration sterilization with 0.22 μm membrane, and controlling pressure at 0.06Mpa for use.

Adding hydroxyethyl cellulose into glycerol, dispersing until no large agglomerated particles exist, adding a second part of phosphate buffer solution, heating in water bath to 90 ℃, mechanically stirring at 450rmp for 35min to completely dissolve, and performing wet heat sterilization at 121 ℃ for 30min for later use.

Mixing and stirring the protein solution subjected to filtration sterilization and the macromolecule gel forming agent subjected to damp-heat sterilization for 20min, filling the mixture into a cavity of a pre-filled and sealed syringe, and freeze-drying according to the following freeze-drying parameters: prefreezing at-30 deg.C for 40min, sublimation drying at-30 deg.C for 20 hr, vacuum controlling at 5Pa, desorption drying at 20 deg.C, and vacuum controlling at 0.5Pa for 6 hr. Freeze-drying to obtain lyophilized powder or sponge. And (3) putting the freeze-dried pre-filled product into a plastic sealing bag for heat seal sealing, and then performing electron beam irradiation sterilization, wherein the sterilization dose is 10.5 KGy.

And packaging the third part of phosphate buffer solution (500 parts) with the pH value of 7.0 in a penicillin bottle, performing moist heat sterilization at the temperature of 121 ℃ for 15min, and providing the product in an aseptic mode.

When the injection is used, auxiliary solution in a penicillin bottle is pumped out by a prepared sterile injector, sterile two-way joints are used for suspending with freeze-dried powder or sponge bi-component pre-filled in the injector, the two injectors are pushed for 30 times to be mixed into transparent gel or milky gel, the freeze-dried powder is redissolved for 2min, and the injection is injected to a part needing to be filled by using a microneedle needle.

The contemplated use of this embodiment is injection filling repair of a bone defect.

Example 3

Accurately weighing: 7 parts of mussel-like mucin, 3000 parts of auxiliary solvent (water for injection), 2 parts of gelling agent (polyvinyl alcohol), 4 parts of cosolvent (polyethylene glycol), 4 parts of protein protective agent (trehalose) and 1 part of pH regulator (acetic acid).

Adding weighed acetic acid, trehalose, and mussel-like mucin into the first part of water for injection, stirring to dissolve, controlling pH at 5.0-7.0, and performing negative pressure filtration sterilization with 0.22 μm membrane under 0.05 Mpa.

Adding polyvinyl alcohol into polyethylene glycol, dispersing until no large agglomerated particles exist, adding into the second part of water for injection, heating in water bath to 85 ℃, mechanically stirring at 350rmp for 25min to completely dissolve, and performing damp-heat sterilization at 121 ℃ for 15min for later use.

Mixing and stirring the protein solution subjected to filtration sterilization and the macromolecule gel forming agent subjected to damp-heat sterilization for 15min, filling the mixture into a cavity of a pre-filled and sealed syringe, and freeze-drying according to the following freeze-drying parameters: prefreezing at-20 deg.C for 30min, sublimation drying at-20 deg.C for 18 hr, and vacuum controlling at 10 Pa. The solution was dried at 30 ℃ for 4 hours under vacuum at 1 Pa. Freeze-drying to obtain lyophilized powder or sponge. And (3) putting the freeze-dried pre-filled product into a plastic sealing bag for heat seal sealing, and then performing electron beam irradiation sterilization, wherein the sterilization dose is 5.5 KGy.

And packaging the third part of water for injection (2000 parts) in a penicillin bottle, performing moist heat sterilization at 121 ℃ for 15min, and providing the sterilized product.

When the injection is used, auxiliary solution in a penicillin bottle is pumped out by a prepared sterile injector, the sterile two-way joint and freeze-dried powder or sponge double components pre-filled in the injector are suspended, the two injectors are pushed for 15 times to be mixed into transparent gel or milky gel, the freeze-dried powder is redissolved for 1min, and the freeze-dried powder is mixed with a bone repair material for bone defect injection filling repair.

The present example contemplates the use of soft tissue filling injection to remove wrinkles.

Example 4

Accurately weighing: 45 parts of mussel-like mucin, 3300 parts of auxiliary solvent (water for injection), 30 parts of gelling agent (methyl cellulose), 20 parts of cosolvent (glycerol), 12 parts of protein protective agent (vitamin E) and 8 parts of pH regulator (acetic acid).

Adding weighed acetic acid, vitamin E and mussel-like mucin into the first part of water for injection, stirring to dissolve, controlling pH at 5.0-7.0, performing negative pressure filtration sterilization by using a 0.20 μm membrane, and controlling pressure at 0.07Mpa for later use.

Adding methylcellulose into glycerol, dispersing until no large agglomerated particles exist, adding into a second part of water for injection, heating in water bath to 95 deg.C, mechanically stirring at 500rmp for 120min to completely dissolve, and wet-heat sterilizing at 135 deg.C for 10 min.

Mixing and stirring the filtered and sterilized protein solution and the heat-moisture sterilized macromolecule gel-forming agent for 25min, filling the mixture into a cavity of a prefilled syringe, and freeze-drying according to the following freeze-drying parameters: prefreezing at-65 deg.C for 10min, sublimation drying at-60 deg.C for 12 hr, and vacuum controlling at 0.1 Pa. The solution was dried at 45 ℃ for 3 hours under vacuum at 0.1 Pa. Freeze-drying to obtain the freeze-dried sponge. And (3) putting the freeze-dried pre-filled product into a plastic sealing bag for heat sealing, and then performing electron beam irradiation sterilization, wherein the sterilization dose is 14.2 KGy.

Packaging the third part of water for injection (1700 parts) in a penicillin bottle, and performing moist heat sterilization at 135 deg.C for 10min to obtain sterile product. When the injection is used, auxiliary solution in a penicillin bottle is pumped out by a prepared sterile injector, the sterile two-way joint and freeze-dried powder or sponge bi-component pre-filled in the injector are suspended, the two injectors are pushed oppositely for 20 times to be mixed into transparent gel or milky gel, the freeze-dried powder is redissolved for 3min, and the injection is injected to a part needing to be filled by a microneedle needle.

The present embodiment contemplates the use of soft tissue shaping.

Example 5

Accurately weighing: mussel-like mucin 1 part, auxiliary solvent 3100 parts (normal saline), gelling agent (carboxymethyl cellulose) 5 parts, cosolvent (glycerin) 5 parts, protein protective agent (trehalose 1.5 parts, mannitol 0.5 part) 2 parts, and pH regulator (acetic acid) 1 part.

Adding weighed acetic acid, mannitol, mussel-like mucin into the first physiological saline solution, stirring to dissolve, controlling pH at 5.0-7.0, performing negative pressure filtration sterilization with 0.22 μm membrane, and controlling pressure at 0.03MPa for use.

Adding carboxymethyl cellulose into glycerol, dispersing until no large agglomerated particles exist, adding into a second part of normal saline, heating in water bath to 50 ℃, mechanically stirring at 50rmp for 120min to completely dissolve, and performing wet heat sterilization at 105 ℃ for 60min for later use.

Mixing and stirring the protein solution subjected to filtration sterilization and the macromolecule gel-forming agent subjected to damp-heat sterilization for 10min, filling the mixture into a cavity of a pre-filled and sealed syringe, and freeze-drying according to the following freeze-drying parameters: prefreezing at-10 deg.C for 60min, sublimation drying at-10 deg.C for 60 hr, and vacuum controlling at 20 Pa. The solution was dried at 15 ℃ under vacuum for 10 hours under 10 Pa. Freeze-drying to obtain the freeze-dried sponge. And (3) putting the freeze-dried pre-filled product into a plastic sealing bag for heat seal sealing, and then performing electron beam irradiation sterilization, wherein the sterilization dose is 5.2 KGy.

And packaging the third part of normal saline (2500 parts) in a penicillin bottle, performing moist heat sterilization at the temperature of 121 ℃ for 20min, and providing the sterilized product. When in use, the auxiliary solution in the penicillin bottle is pumped out by a prepared sterile syringe, and the sterile two-way joint and the freeze-dried powder or the sponge bi-component pre-filled in the syringe are suspended, wherein the freeze-dried powder is redissolved for 2min, the two syringes are pushed for 40 times to be mixed into transparent gel or milky gel, and the transparent gel or the milky gel is pushed into a damaged skin area and is lightly and uniformly smeared by hands.

The contemplated use of this example is wound repair.

Example 6

The difference from example 1 is that 14 parts of the protein protectant in example 6 is prepared by compounding two protein protectants (7 parts of trehalose and 7 parts of mannitol).

Example 7

The difference from example 1 is that 12 parts of the protein protective agent in example 7 is compounded by three protein protective agents (5 parts of trehalose, 2 parts of sorbitol and 5 parts of tea polyphenol).

Comparative example 1

The components are prepared according to the mixture ratio of the embodiment 1, and freeze-drying is not carried out after the two components are mixed, and radiation sterilization is carried out after direct filling.

Comparative example 2

The difference from example 1 is that the raw material mussel-like mucin is replaced by naturally extracted mussel mucin.

Comparative example 3

The difference from example 1 is that no protein protectant was used.

Comparative example 4

The difference from example 6 is that the protein protectant is ethylene glycol.

Animal experiment for wound repair effectiveness

(1) Test mice sample size 30

(2) Hair removal

The hair on the back of the mouse is removed, then the part is washed by warm water, and a cotton ball is wiped dry for standby.

(3) Modeling and treatment method

Mice were anesthetized with 2.5% sodium pentobarbital at 1mL/kg along the marginal ear vein. The depilatory part is divided into three areas of 1.5 × 1.5cm, and irradiated with laser beam at 90 deg. perpendicular to the skin surface, and the irradiated part is coated with cold gel for protection before each irradiation. By adopting the 6-grade laser pen, the skin of the mouse can be burned by laser, and the mouse shows more serious erythema and can form superficial scars. In three zones, the application product and control were performed as in figure 1, and a blank control was performed.

Grouping description: experimental groups used the samples of example 1, using mussel-like mucin feed. The control group used the sample of comparative example 2 and used a naturally extracted mussel mucin feed. The blank control group was saline.

All animals were dosed 2 times a day (once in the morning and once in the evening) for the first 7 days, with the specific dose being based on the wound surface.

(4) Evaluation method

After 1 week of repair and nursing, the skin surface of the mouse is observed with naked eyes for micro-damage, superficial scar tissue erythema and scar formation.

Effect determination criteria: the effect is shown: macroscopic erythema, scar area regression > 50%; improvement: macroscopic erythema, scar area regression > 30%; and (4) invalidation: visual erythema and scar area regression of < 30%. The total effective rate is calculated by obvious effect and improvement.

Secondly, taking the wound surface tissue to carry out pathological HE examination: randomly extracting one mouse on the 3 rd day, the 7 th day and the 28 th day, and taking the wound surface tissues of the experimental group, the control group and the blank control group for pathological HE examination.

Results (1): as shown in the following figure 2, after the administration of the drug for 3 days, the wound surfaces of the experimental group and the control group are obviously reduced, the improvement of the blank control group is not obvious, the color of the wound surfaces of the experimental group and the control group is obviously lightened after the administration of the drug for 7 days, the wound surfaces of the experimental group and the control group disappear after the administration of the drug for 28 days, and only a very light wound surface of the blank control group is basically healed; prove that the effect of the mussel-like mucin repair wound surface of the application is obvious, and the naturally extracted mussel mucin added in the sample of the contrast group has the same wound surface repair effect, even the effect is slightly better than that of the contrast group, and the better repair effect can be embodied in a short time.

The observation and statistics of the test results show that the sample area of the example 1 is used for 24 cases, 6 cases and 0 case; the control sample area of comparative example 2 was used for 21 cases, 9 improved cases and 0 ineffective cases; the physiological saline area showed 4 cases of effect, 10 improved cases, and 16 ineffective cases. The gel of the application and the physiological saline have significant difference (P <0.01) and have no adverse reaction.

Results (2): as can be seen from the HE pathology examination in fig. 3 below, at day 3, the epidermis of the experimental group (sample of example 1) was substantially continuous, with a clear structure and inflammatory cell infiltration in the epidermis; the epidermis of the control group (sample of comparative example 2) had inflammatory cell infiltration; the blank control group (normal saline group) has discontinuous epidermis and less clear structure, and more inflammatory cells infiltrate into the epidermis; on day 7, the wounds of the experimental group (sample of example 1) and the control group (sample of comparative example 2) substantially restored normal skin structure.

And (4) conclusion: it can be seen by observing the repair situation of the wound surface that after the samples of example 1 and comparative example 2 are continuously used for 7 days, the erythema of the wound surface is obviously reduced, superficial scars are obviously reduced, and the wound surface area basically recovers the normal skin structure, which shows that the technical scheme of the application can effectively repair the micro-damage and barrier damage of the skin and has equivalent efficacy to the natural mussel mucin product.

And (3) detecting the content of the dopa stored at normal temperature of the product:

(1) the instrument comprises the following steps: UV-265 ultraviolet-visible spectrophotometer, pH S-3C acidity meter.

(2) Reagent: 100 mu g/mL of dopamine standard stock solution (chemical reference, China institute for drug and biological products), accurately weighing 0.01g of dopamine, diluting the dopamine to 100mL with secondary water, storing the dopamine at 4 ℃, and diluting the dopamine to 40 mu g/mL of working solution when in use. NaNO2(10g/L) aqueous solution, and was stored under dark conditions. HAc-NaAc buffer solution (pH 5.90), 0.1mol/L HAc and 0.1mol/L NaAc were mixed at a volume ratio of 1: 16.

(3) The detection method comprises the following steps: accurately transferring 2mL of 40 mu g/mL dopamine standard solution into a 10mL colorimetric tube, and adding NaNO ₂ 2mL of the solution and 5mL of HAc-NaAc buffer solution are shaken up and placed in a boiling water bath for heating for 3.5 min. Taking out, cooling to room temperature with running water, diluting with water to scale, and shaking. The absorbance was measured at 300nm using a 1cm cuvette with a reagent blank as a reference. A standard curve was prepared according to the above method, and the samples of example 6 were processed in the same manner, and absorbance was measured to calculate the dopa content, and the results are shown in Table 1 below. Blank control is dopa solution of the same concentration as in example 6.

TABLE 1 dopa content measurement of samples stored at room temperature for different periods of time

The data in table 1 show that, by adopting the technical scheme of the invention, the dopa content in the sample is changed very little and is maintained within an acceptable range during the storage at normal temperature for 0-6 months, while the dopa content in the blank control group is obviously reduced in the storage process, and is reduced by more than 50% even when the blank control group is stored for 6 months, which indicates that the sterilization mode after freeze drying provided by the invention can effectively avoid the problem of oxidation of dopa groups, and the core efficacy component mussel mucin can maintain the bioactivity thereof.

Comparison of Effect of irradiation dose on protein stability

The experimental process comprises the following steps: the mixed solution before freeze-drying in example 1 was bottled and sealed, and then subjected to 7KGy, 14KGy and 21KGy irradiation sterilization, and the sterilized products were placed at room temperature, respectively, and the appearance change of the samples was observed. The results are shown in table 2 below and fig. 4.

TABLE 27 KGy, 14KGy, 21KGy storage Effect tables after radiation sterilization

Appearance of the product	7KGy	14KGy	21KGy
				Storing at room temperature for 1 day	Light yellow clear liquid	Slightly ashed clear liquid	Yellowish slightly turbid liquid
Storing at room temperature for 1 month	Light yellow clear liquid	Yellowish clear liquid	Yellowish slightly turbid liquid
				Storing at room temperature for 3 months	Light yellow clear liquid	Yellowish clear liquid	Little protein is separated out
Storing at room temperature for 6 months	Light yellow clear liquid	Yellowish slightly turbid liquid	Massive protein block precipitation

The mussel-like mucin contains a large amount of dopa groups in the moleculeThe hydroxyl group is active, phenolic hydroxyl in the dopa group is easily oxidized into quinone, and the oxidized dopa group and the unoxidized dopa group are crosslinked to form a high molecular polymer which is separated out from the solution. Experiments show that the mixed solution can be directly separated out after being irradiated by 25KGy for sterilization, the protein is not separated out after being irradiated by 7KGy, 14KGy and 21KGy, as shown in figure 4, after being stored at normal temperature for 6 months, the solution color is gradually deepened, the 21KGy protein is separated out in a flocculent shape, the 14KGy protein is separated out in a small amount when being stored for 6 months, and the low-dose 7KGy irradiated sample is not separated out after being stored at normal temperature for 6 months, which is relatively stable, so that the low-dose irradiation is proved to be favorable for the stability of the protein; the sterile test (table 3 below) also proves that according to the technical scheme of the invention, the stability of the product can be ensured under the low irradiation dose (5.2-14.2 KGy), the mussel-like mucin precipitation and precipitation are avoided, and the sterile guarantee level (10) can be achieved ^-6 )。

Table 3 example 1 samples were stored for sterility test results at different irradiation doses

Comparison of Effect of Freeze-drying irradiation and solution irradiation on protein molecular weight variation

The experimental process comprises the following steps: the lyophilized powder prepared in example 1 and the non-lyophilized solution were sterilized by irradiation with different irradiation doses, and the change in molecular weight of protein before and after irradiation was examined by SDS-PAGE gel electrophoresis, and the results are shown in FIG. 5.

As shown in fig. 5: a is a strip before sterilization of the freeze-dried powder in example 1, b is a protein strip shown after 15KGy irradiation of the freeze-dried powder in example 1, c is a protein strip after 5KGy irradiation of the solution in comparative example 1, d is a protein strip after 7.5KGy irradiation of the solution in comparative example 1, e is a protein strip after 15KGy irradiation of the solution in comparative example 1, and f is a protein strip after 25KGy irradiation of the solution in comparative example 1.

Comparing a and b, the fact that protein molecules are almost indistinguishable before and after irradiation by adopting freeze-drying and low-dose irradiation shows that degradation of mussel-like mucin caused by irradiation can be remarkably prevented by adopting a freeze-dried powder or freeze-dried sponge form. The bands c, d, e and f show that the mussel-like mucin is almost completely degraded after the protein solution is irradiated, and that the mussel-like mucin is not resistant to irradiation in the solution and is almost completely degraded even at a lower dose of 5 KGy. Therefore, the method for low-dose irradiation and freeze-drying and then irradiation sterilization can ensure the sterility level of the product and effectively avoid the degradation of mussel-like mucin by irradiation.

Freeze-dried powder/freeze-dried sponge normal temperature storage stability

Description of the experimental procedures: the sample of example 3 was stored at room temperature for 6 months, and the stability of the protein was checked by SDS-PAGE gel electrophoresis, and the results are shown in FIG. 6.

As shown in fig. 6-1, lanes a, b are protein electrophoresis bands of lyophilized powder stored at 0 month after sterilization; as shown in FIG. 6-2, lane c, d are protein electrophoresis bands of lyophilized powder stored at room temperature for 6 months. Comparing fig. 6-1 and fig. 6-2, it can be seen that the protein molecules are almost unchanged after the freeze-dried powder is stored at normal temperature for 6 months, which indicates that by adopting the technical scheme of the invention, the mussel-like mucin gel is stored at normal temperature for 6 months in a freeze-dried state (freeze-dried powder or freeze-dried sponge), and the product is stable and is not degraded.

As shown in FIG. 7, lanes a, b, c, d, e and f are the same as those of the samples of example 2 and comparative example 4, respectively, as determined by SDS-PAGE gel electrophoresis.

The SDS-PAGE gel electrophoresis of FIG. 7 was subjected to grayscale analysis using the analysis software Image J, and the results are given in Table 4 below:

TABLE 4 grayscale analysis of SDS-PAGE gel electrophoresis

As can be seen from fig. 7 and the data in table 4 above, without using a protein protectant (comparative example 3), even in a manner of freeze-drying prior to irradiation, the structure of the mussel-like mucin in the system is completely destroyed, resulting in complete degradation of the mussel-like mucin, and the result is comparable to that of solution irradiation; the damage of irradiation to the mussel-like mucin in a system can be effectively avoided by adding the protein protective agent, wherein the color of a target protein band of a sample added with the two protein protective agents is obviously darker than that of a protein band of a single protein protective agent; in addition, as can be seen from the gray scale analysis data, the ratio of the target protein in the system using trehalose and other protein protective agents in combination (example 6) is significantly higher than that in the system using only one protein protective agent of the present invention, and by analyzing the gray scale data of examples 6 and 5, it is further illustrated that the protective effect on the target protein is optimal and the degradation of the target protein band is very little when trehalose and other protein protective agents are used in the preferable range of 0.2-1.5: 1, which means that the anti-oxidation effects of trehalose to stabilize the protein structure and other protective agents are simultaneously exerted in the way of combining trehalose and other protein protective agents, and the two agents synergize to realize the effective protection on mussel-like mucin in the system and the most stable system.

According to the wound repair effectiveness-animal experiments, the mussel-like mucin gel has equivalent efficacy and safety to those prepared by adopting the naturally extracted mussel mucin, and the mussel-like mucin gel has obvious wound repair effect, and can reflect the effect in a short time; the contrast of the influence of the protein stability by low-dose irradiation and high-dose irradiation is known, and the low-dose irradiation is beneficial to the protein stability; the contrast of the influence of the irradiation of the freeze-dried powder and the irradiation of the solution on the change of the molecular weight of the protein can be known, so that the mussel-like mucin is more suitable for being stored in an anhydrous system; the stability of the freeze-dried powder at normal temperature is known, and the freeze-dried powder is stable under the condition of 6 months of normal-temperature storage.

Therefore, the mussel-like mucin gel of the invention is prepared by freeze-drying the gel into powder or separating the sponge and the auxiliary solvent, the mussel-like mucin exists in the freeze-dried powder or the sponge, low-dose radiation sterilization can be adopted, the product can be stored at normal temperature, the mussel-like mucin can be effectively stored, and the protein stability is facilitated; and the freeze-dried powder or the sponge can effectively avoid the degradation or oxidation crosslinking precipitation of protein molecules in the storage period. The problem that dopa groups contained in mussel-like mucin are easy to oxidize can be solved, so that the storage condition of the gel is changed from special refrigeration or freezing storage into conventional normal-temperature storage, the storage, storage and transportation costs are saved, and the use is more convenient; meanwhile, the number of initial pollution bacteria is effectively controlled through filtration sterilization, so that the freeze-dried powder can be subjected to low-dose irradiation sterilization, the damage of high-dose irradiation to protein components is effectively avoided, and the stability of the protein is ensured.

Meanwhile, the animal experiment, which is the effectiveness of wound repair, also proves that the mussel-like mucin gel has an obvious effect of repairing wounds. The main material of the mussel-like mucin gel is mussel-like mucin, which is a recombinant protein consisting of 6 MAP1 (fp-1) decapeptide repetitive sequences at C end and N end of MAP5 (fp-5) type and is a gene recombinant fp-151 type, the expression quantity of the recombinant hybrid protein is high, the purification is simple, the biocompatibility is high, the protein is mainly prepared by adopting genetically recombinant escherichia coli engineering bacteria through biological fermentation culture, purification and freeze-drying, the prior fermentation and purification technology is mature, the yield is high, and the industrial production requirement is met. The mussel-like mucin prepared by constructing a target strain through genetic engineering and adopting a biological fermentation technology has the same amino acid sequence as the naturally extracted mussel mucin, and has good biocompatibility and bacteriostasis; meanwhile, the modified mussel-like mucin contains a large amount of dopa groups as does naturally extracted mussel mucin. That is, the mussel-like mucin contains a large amount of 3, 4-dihydroxyphenylalanine (DOPA ) in the molecule, and in clinical use, the mussel-like mucin in the freeze-dried powder or the freeze-dried sponge is mixed with an auxiliary solvent to form an aqueous gel system, under the system, some phenolic hydroxyl groups in the DOPA are oxidized into quinones, and the oxidized DOPA and unoxidized DOPA are crosslinked to form a high molecular network polymer, and the assembly forms a transparent film which allows water vapor and air to pass through; meanwhile, the mussel-like mucin has high adhesion property, can be strongly adhered to the wound surface, and has the effects of inhibiting bacteria and promoting wound healing. The invention prepares different gel materials by adjusting the proportion of the freeze-dried powder or the sponge and the auxiliary solvent, is suitable for different clinical purposes, can be applied to preparing products for wound repair, soft tissue filling, bone repair and the like, and can be used for repairing wounds after medical and art, filling and removing wrinkles of faces as an implant, injecting, filling and repairing bone defects and the like.

The technical contents of the present invention are further illustrated by the examples, so as to facilitate the understanding of the reader, but the embodiments of the present invention are not limited thereto, and any technical extension or re-creation based on the present invention is protected by the present invention.

Claims

1. The mussel-like mucin gel is characterized by comprising the following components in parts by weight:

the protein protective agent is at least one selected from trehalose, alginate oligosaccharide, sorbitol, mannitol, superoxide dismutase, vitamin C, vitamin E and tea polyphenol.

2. The mussel-like mucin gel according to claim 1, wherein the mussel-like mucin is of the fp-151 type and is a recombinant protein consisting of 6C-terminal and N-terminal decapeptide repeats of the MAP1 type (fp-1) type (fp-5) of MAP5 type.

3. The mussel-like mucin gel of claim 1, wherein the gelling agent is selected from at least one of hydroxyethylcellulose, methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, xanthan gum, sodium alginate, sodium polyacrylate, carbomer, polyvinyl alcohol, polyvinyl pyrrolidone, or other non-ionic thickening agents.

4. The mussel-like mucin gel according to claim 1, wherein the protein protecting agent is trehalose or a mixture comprising trehalose and at least one of alginate oligosaccharides, sorbitol, mannitol, superoxide dismutase, vitamin C, vitamin E, tea polyphenols.

5. The mussel-like mucin gel of claim 1, wherein the co-solvent is selected from at least one of polyethylene glycol, glycerol, propylene glycol, butylene glycol, pentylene glycol, glyceryl polyether-26; the pH regulator is at least one selected from citric acid, boric acid, acetic acid, phosphoric acid and hydrochloric acid; the auxiliary solvent is at least one selected from normal saline, phosphate buffer and water for injection.

6. A method for preparing a mussel-like mucin gel according to any one of claims 1 to 5, comprising the steps of, in order:

mixing the solution A and the solution B, and freeze-drying and sterilizing to obtain freeze-dried powder or freeze-dried sponge;

(2) preparing gel: and mixing the sterilized third auxiliary solvent with the freeze-dried powder or the sponge to obtain the mussel-like mucin gel.

7. The method for preparing a mussel-like mucin gel according to claim 6, wherein in step (1), the conditions for filtration sterilization are as follows: pH 5.0-7.0, filtering with 0.1-0.45 μm membrane for sterilization; the moist heat sterilization conditions are as follows: the sterilization temperature is 105 ℃ and 130 ℃, and the sterilization time is 5-60 min; the sterilization is irradiation sterilization, and the irradiation dose is 5.2-14.2 KGy.

8. The method for preparing the mussel-like mucin gel according to claim 6, wherein in the step (1), the freeze-drying process conditions are as follows: pre-freezing at-10 deg.C to-65 deg.C for 10-60min, sublimation drying at-10 deg.C to-60 deg.C for 12-48h, sublimation drying vacuum degree of 0.1-20Pa, desorption drying at 15-45 deg.C for 3-10h, and desorption drying vacuum degree of 0.1-10 Pa.

9. The method for preparing the mussel-like mucin gel according to claim 6, wherein in the step (2), the mass ratio of the sterilized third auxiliary solvent to the lyophilized powder or sponge is 254: 1-10: 1.

10. the mussel-like mucin gel of claim 1, for use in the preparation of wound repair, soft tissue augmentation, bone repair products.